Skip to main content
. 2009 Nov 30;187(5):669–683. doi: 10.1083/jcb.200906014

Figure 2.

Figure 2.

Effect of hbdPRELP in vivo. Ovariectomized (OVX) mice were treated with vehicle, 10 mg/kg body weight of hbdPRELP, or control peptide and 1 mg/kg body weight of alendronate as reference drug 5 d/wk for 5 wk. (A) Quantification of the bone resorption marker CTX in urine samples. (B) Tibial sections stained for TRAcP activity (purple stain) to evidence osteoclasts. (C–H) Measurement of osteoclast number/bone surface (OcN/BS; C), osteoclast surface/bone surface (OcS/BS; D), bone volume/tissue volume (BV/TV; E), trabecular number (Tb N; F), trabecular thickness (Tb Th; G), and trabecular separation (Tb Sp; H). (A and C–H) Data are the mean ± SD of five mice per group (*, P < 0.05 vs. sham; #, P < 0.05 vs. control peptide and vehicle; and +, P < 0.05 vs. control peptide).